Fluart Innovative Vaccines Ltd. is not only a pioneer in the development and production of influenza vaccines but also extends its expertise to Contract Development and Manufacturing (CDMO) services. Established in 1991 by a dedicated team of scientists and researchers with a profound commitment to public health, Fluart has become a trusted name in the Hungarian pharmaceutical landscape.
Adhering to stringent Good Manufacturing Practice (GMP) standards, Fluart’s vaccines have earned approval from the Hungarian National Institute of Pharmacy and Nutrition, ensuring the highest quality and safety. Beyond its core focus on influenza vaccines, Fluart actively engages in contract development and manufacturing operations, providing comprehensive solutions to partners in the pharmaceutical industry.
In addition to its commitment to producing high-quality vaccines, Fluart remains at the forefront of influenza vaccine research. The company is dedicated to exploring innovative approaches to vaccine development, contributing to advancements in the field.
A cornerstone of Fluart’s mission is to make its vaccines accessible to those in need. The company strives to balance excellence in research and development with a social responsibility to ensure that its vaccines are affordable and within reach for diverse populations.
As a testament to its success, Fluart Innovative Vaccines Ltd. stands as a leading supplier of influenza vaccines in Hungary, exemplifying a commitment to public health, innovation, and accessibility.